[ad_1]
The news of a Chinese candidate vaccine, which has been shown to be 86% effective in protecting people from the coronavirus, is encouraging, based on interim results from a phase 3 trial in the United Arab Emirates.
It is the vaccine from the state pharmaceutical industry, Sinopharm, which has already been tested in approximately one million people in China.
This percentage may be lower than Western approved Pfizer / BioNTech, Moderna and AstraZenecca vaccines (90% and above), but is still well above the minimum acceptable rate of 50%.
Sinopharm vaccine has the additional advantage that it can be stored under simple refrigeration and does not require deep freezing like other vaccines.
“This makes the Sinopharm vaccine a potential candidate for many countries, especially emerging markets that do not have immediate access to vaccines from the West. The vaccine can be stored at normal refrigerator temperatures, unlike BioNTech / Pfizer vaccines. and Modern. “This makes it an attractive option for developing countries without advanced supply refrigeration infrastructure,” notes the Wall Street Journal.
Some information about the Sinopharm vaccine
Phase 3 testing of the Sinopharm vaccine began in July. About 31,000 volunteers participated, testing two versions of the vaccine: one developed in a laboratory in Beijing and another in a laboratory in Wuhan.
The UAE had previously announced that 1/3 of the participants took placebo, while two-thirds took the Beijing version. However, the exact number of participants is unknown.
The UAE has registered this vaccine for emergency use since September.
Although some of those who received the vaccine became infected, according to the company and the United Arab Emirates, the vaccine was 100% effective in preventing moderate to severe cases of the disease.
The analysis also showed that 99% of the participants developed antibodies against the disease, according to the statement.
The candidate vaccine from Sinopharm, or China National Pharmaceuticals Group, is based on an inactivated virus, meaning that the pathogen is attenuated for use in humans.
“The Sinopharm results are in contrast to another Chinese Covid-19 vaccine, the CoronaVac candidate from Sinovac Biotech Ltd., which showed vague results in early tests on its level of protection,” he said.
at google news and be the first to know all the news
[ad_2]
